The aetiology and pathogenesis of rheumatiod arthritis

Hospital Pharmacist

Volumn 9, Issue 1, 2002, Pages 5-10

  Buch, Maya ^a   Emery, Paul ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CELL ADHESION MOLECULE; CHEMOKINE; CORTICOTROPIN RELEASING FACTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; ESTROGEN; HEAT SHOCK PROTEIN; HLA ANTIGEN; HLA DR ANTIGEN; HLA DR4 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PROGESTERONE; PROSTAGLANDIN E2; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

B LYMPHOCYTE; CELL INFILTRATION; EPSTEIN BARR VIRUS; GENDER; GENETIC PREDISPOSITION; HUMAN; JOINT RADIOGRAPHY; LENTIVIRINAE; MORTALITY; MYCOBACTERIUM; MYCOPLASMA; PARVOVIRUS; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; T LYMPHOCYTE; YERSINIA;

EID: 0036146819     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis
2. Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 years
3. Mortality in rheumatoid arthritis: Have we made an impact in four decades?
4. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: A study of incidence, prevalence and mortality
5. Recent onset arthritis in the elderly: A five-year longitudinal observational study
6. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: A retrospective cohort study from disease onset
7. Evidence for oxidised low-density lipoprotein in synovial fluid from rheumatoid arthritis patients
8. Lipid profiles in untreated patients with rheumatoid arthritis
9. Contribution of genetic factors to rheumatoid arthritis
10. Occurrence of rheumatoid arthritis in a nationwide series of twins
11. Twin concordance rates for rheumatoid arthritis: Results from a nationwide study
12. Characterising the quantitative genetic contribution to rheumatoid arthritis using data from twins
13. The shared epitope hypothesis - An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
14. Predictive value of interleukin-1 gene polymorphisms for surgery
15. Primary association of tumour necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis
16. Different gene loci within the HLA-DR and TNF regions are independently associated with susceptibility and severity in Spanish rheumatoid arthritis patients
17. Pregnancy and its effect on the risk of developing rheumatoid arthritis
18. Human placenta-eluted gamma globulins in immunomodulating treatment of rheumatoid arthritis
19. Identification of class II HLA alloantibodies in placenta-eluted gamma globulins used for treating rheumatoid arthritis
20. Corticotrophin-releasing hormone directly and preferentially stimulates dehydroepiandrosterone sulphate secretion by human adrenal cortical cells
21. Adrenal and gonadal steroid deficiency in the pathogenesis of rheumatoid arthritis
22. Maintained pregnancy levels of oestrogen afford complete protection from post-partum exacerbation of collagen-induced arthritis
23. Reduction in incidence of rheumatoid arthritis associated with oral contraceptives
24. Diminished incidence of severe rheumatoid arthritis associated with oral contraceptive use
25. Heat-shock proteins: A link between rheumatoid arthritis and infection?
26. Role of cytokines in rheumatoid arthritis
27. In situ hybridisation of interleukin-1 in CD14-positive cells in rheumatoid arthritis
28. Localisation of tumour necrosis factor alpha in synovial tissues at the cartilage-pannus junction in patients with rheumatoid arthritis
29. The pathophysiology of tumour necrosis factors
30. Increased levels of soluble tumour necrosis factor receptors in sera and synovial fluid of patients with rheumatic diseases
31. Binding of IL-1 alpha, IL-1 beta and IL-1 receptor antagomst by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids
32. IL-1 receptor antagomst protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium
33. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
34. Antitumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis
35. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
36. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-alpha
37. Randomised double-blind comparison of a chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis
38. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein
39. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
40. Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial
41. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
42. A multicentre, double-blind, dose ranging, randomised, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
43. Excessive production of interleukin-6/B-cell stimulatory factor-2 in rheumatoid arthritis
44. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis
45. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis
46. Therapy of RA by blocking IL-6 signal transduction with humanised anti-IL-6 receptor antibody
47. Angiogenesis and rheumatoid arthritis; pathogenic and therapeutic implications
48. The vascular endothelial growth factor family of polypeptides
49. Chemokines in rheumatoid arthritis
50. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis